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Abstract
Nodal status at the time of presentation for oral cavity carcinoma is the most 
important prognostic factor. Neck dissection is warranted for T3/T4 oral cavity 
carcinoma but there has been an ongoing controversy in the treatment of clini-
cally negative neck in T1/T2. The risk of occult metastases in N0 squamous cell 
carcinoma of the oral cavity is 20–30%, and was found highest for tongue carci-
noma. Elective neck dissection is recommended for T2N0 tongue carcinoma, and 
Stage I clinically N0 oral cavity carcinoma with tumor thickness >3 mm. CT scan 
has the highest sensitivity in detecting occult cervical lymph node metastases. 
Sentinel lymph node biopsy, as well as identification of biomarkers, continue to 
show increased utility. This chapter aims to discuss the methods of detecting nodal 
metastasis, the need for elective neck dissection for clinically neck node negative 
T1/T2 oral cavity carcinoma, the role of watchful waiting in N0 necks, the impact 
of tumor thickness in the risk for cervical lymph node metastasis, the role of 
sentinel lymph node biopsy in the detection of occult lymph node metastasis, and 
the role of biomarkers as predictors of occult lymph node metastasis.
Keywords: oral cavity carcinoma, neck dissection, elective neck dissection, 
occult cervical metastases
1. Introduction
Nodal status at the time of presentation for oral cavity carcinoma is the most 
important prognostic factor [1]. If the nodes are affected, the chance for cure is 
reduced by half [1, 2]. Historically, Shah et al., as early as 1990, demonstrated that 
levels I, II, and III were at greatest risk for nodal metastases from primary squamous 
cell carcinoma of the oral cavity [3]. Yuen et al. showed that the rate of cervical 
metastases is greatest for carcinoma of the oral tongue and floor of mouth, with the 
rate increasing with increasing T stage [4]. Curative surgery involves wide exci-
sion of the primary and neck dissection [1]. For T3/T4 oral cavity carcinoma, neck 
dissection is warranted even for clinically negative necks [1]. There has long been an 
ongoing controversy in the treatment of clinically negative neck in early stage oral 
cavity carcinoma (T1/T2) [1, 4, 5].
This chapter will discuss the methods of detecting nodal metastasis, the need for 
elective neck dissection for clinically neck node negative T1/T2 oral cavity carci-
noma, the role of watchful waiting in N0 necks, the impact of tumor thickness in 
the risk of cervical lymph node metastasis, the role of sentinel lymph node biopsy 
in the detection of occult lymph node metastasis, and the role of biomarkers as 
predictors of occult lymph node metastasis.
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2. Detection of nodal metastasis
It has been shown that the sensitivity, specificity, and accuracy of detection of 
neck metastases by clinical examination are 70, 65, and 68%, respectively; with an 
overall error of 20–30% [6].
Various imaging modalities are being utilized to detect nodal metastasis and 
are found to be more reliable than clinical palpation. These include computerized 
tomography (CT) scan, magnetic resonance imaging (MRI), ultrasound, and 
positron emission tomography (PET) scan. These modern imaging modalities 
offer similar diagnostic accuracy to diagnose clinically N0 neck [7]. Sensitivity is 
comparable across all modalities but CT Scan has been shown to offer the highest 
specificity [8, 9]. A most recent study by Bae et al. in 2019 showed a higher sensi-
tivity for detection of occult metastasis with PET CT than that for CT/MRI for 42 
patients [10].
Despite the quality of current imaging modalities, the risk of occult metastases 
in necks categorized as N0 in patients with oral cavity squamous cell carcinoma 
(SCC) has been reported to be between 20 and 30% [8].
3.  Elective neck dissection for clinically neck node negative T1/T2 Oral 
cavity carcinoma
The rate of occult lymph node metastasis in T1 to T2 oral cavity carcinoma 
reaches as high as 34% [11–13]. Personal data from the experience of the authors 
showed an occult regional neck nodal metastasis rate of 25% (n = 4) for Stage I and 
27.8% (n = 18) for Stage II oral cavity carcinoma.
The decision to observe or treat the N0 neck is left to the choice of the patient and 
the head and neck oncologist [6]. In oral cavity carcinoma, the only clinically N0 
necks for which observation is appropriate are those associated with T1/T2 lip carci-
nomas, T1/T2 oral tongue carcinomas that are less than 4 mm thick, and T1/T2 floor 
of mouth cancers less than or equal to 1.5 mm thick [6]. A most recent systematic 
review by Cao et al. showed that elective neck dissection could significantly decrease 
neck recurrence and improve disease-free survival and overall survival compared to 
watchful waiting for patients with cT1-T2N0 oral cavity carcinoma [14].
Particularly for early stage (Stage I and Stage II) oral cavity carcinoma, previous 
studies have shown a lower risk of regional recurrence rate with elective neck dis-
section compared to watchful waiting [11, 15–18]. Five-year survival rate is higher 
for elective neck dissection versus watchful waiting; and specific death rate from 
regional recurrence is less for elective neck dissection than watchful waiting [11, 
17, 18]. Regional recurrence rate for 154 Stage I and II N0 patients was found to be 
higher for patients who did not receive elective neck dissection [11].
4. Neck dissection general recommendations for Oral cavity carcinoma
The standard treatment for N0 neck (and even N1) is neck dissection of levels 
I, IIA, and III [19]. However, when level IIA is involved, there is a 22% risk of 
level IIB involvement, therefore, level IIB has to be included in the dissection [19]. 
Controversy about level IV involvement has come into play which may justify its 
dissection because of a reported 15% risk of involvement [20, 21]. Level V is rarely 
involved in oral cavity that is why it is hardly resected.
For N2/N3, neck dissection of levels I to V are indicated with or without resec-
tion of IJV, SCM, or SAN [1].
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5.  The impact of tumor thickness in the risk of cervical lymph node 
metastasis and the role of sentinel lymph node biopsy
The National Comprehensive Cancer Network Guidelines (2019) recommends 
that elective neck dissection be based on the risk of occult metastasis in the appro-
priated nodal basin [1]. Selective neck dissection of at least levels I–III is recom-
mended for N0 oral cavity carcinoma.
Particularly, for oral cavity squamous cell carcinoma, sentinel lymph node 
biopsy or the primary tumor depth of invasion should guide decision making and 
these are currently the best predictors of occult metastatic disease [1, 22]. Earlier 
versions of NCCN state that for Stage I clinically N0 oral cavity cancer, elective 
neck dissection is recommended for tumor thickness >4 mm but recent evidence 
supports the effectiveness of elective neck dissection in patients with oral cavity 
cancers >3 mm depth of invasion [1, 22].
It is worthy of mention that the recently proposed 8th edition of the American Joint 
Committee on Cancer (AJCC) staging system for oral cavity squamous cell carcinoma 
is the addition of depth of invasion (DOI) as a modifier for the T category in the TNM 
staging [23]. It remains a controversy whether it is reasonable to substitute tumor 
thickness for DOI, since tumors with a larger DOI or thickness are associated with 
an increased risk of nodal metastasis and worse survival outcomes [24]. It has been 
concluded in a 2017 study by Dervin et al. that the T category and TNM stage prognos-
tic performance of the eighth edition AJCC staging of oral cancer is similar regardless 
of whether DOI or thickness is used as the T-category modifier; hence, in centers or 
institutions without complete DOI data, it is reasonable to use tumor thickness [24].
Accuracy of sentinel lymph node biopsy for nodal staging of early oral cavity 
carcinoma has been tested extensively against the reference standard of immedi-
ately performed neck dissection or subsequent extended follow-up, with a pooled 
estimate of sensitivity of 0.93 and negative predictive values ranging from 0.88 to 1, 
with comparable survival outcomes [1, 22, 25–29]. A more recent systematic review 
revealed that sentinel lymph node biopsy is advantageous because it improves the 
accuracy of tumor staging, is a minimally-invasive procedure, avoids unnecessary 
nodal dissection, and results in limited morbidity and mortality with negative 
predictive value of 90–95% [6]. The disadvantages include posing difficulty for 
peri-tumoral injection for bulky invasive primary tumors that invade adjacent 
anatomic subsites, difficulty in floor of mouth tumors and those with proximity to 
the draining lymphatic basin, clinically positive nodes that are difficult to be identi-
fied by sentinel node mapping because of poor uptake of tracer, and the need for 
additional second stage surgery in case of positive neck node [6].
In addition, sentinel lymph node biopsy is a technically demanding procedure, 
with its success rates for sentinel node and occult lymphatic metastasis identification 
much dependent on technical expertise and experience [1]. Thus, sufficient caution 
must be exercised when offering it as an alternative to elective neck dissection [1].
6. Biomarkers as predictors of occult lymph node metastasis
Table 1 shows the various biomarkers which have been studied to detect occult 
lymph node metastasis.
Harada et al. showed that in normal squamous epithelium, cyclin B1 was local-
ized in the nucleus and was expressed only in several cells of the basal and parabasal 
layers. In tumor tissues, however, cyclin B1 was expressed mainly in the cytoplasm. 
Cyclin B1 overexpression was positively correlated with occult cervical lymph node 
metastases and the number of mitotic cells [30].
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Zhang et al. showed that the secreted protein acidic and rich in cysteine 
(SPARC) has a positive rate in 49.1% of tongue cancer tissues and 0% in normal 
tissues. The expression of SPARC was positively correlated with occult lymph node 
metastasis and recurrence [31].
Huber et al. showed that the differentiation grade and down-regulation of 
E-cadherin expression significantly correlate with positive lymph node status in 
univariate and multivariate analyses. Thus, E-cadherin immunohistochemistry may 
be used as a predictor for lymph node metastasis in squamous cell carcinoma of the 
oral cavity and oropharynx [32].
Huber et al. showed that podoplanin expression correlated significantly with 
sentinel lymph node metastasis and remained a significant predictor for lymph 
node status even after controlling for tumor stage [33]. In relation to this, a more 
recent study revealed the association of podoplanin and SOX2 in the progression 
of oral squamous cell carcinoma [34]. OX2 is a transcription factor related to the 
maintenance of stem cells in a pluripotent state. Podoplanin is a type of trans-
membrane sialoglycoprotein, which plays an important role in tumor progres-
sion and metastasis [34]. There was a significant inverse correlation between 
the expression of SOX2 and podoplanin with the tumor grade, survival analysis 
showed that a high expression of SOX2 correlated positively with the disease-free 
survival, and a significant positive association between the pattern of SOX2 and 
podoplanin expression [34].
Mäkinen et al. showed that matrix metalloproteinase-7 (MMP-7) expression was 
associated with presence of occult metastases (OR 3.67; p = 0.013); increased inva-
sion depth (OR 4.60; p = 0.005); high tumor grade (OR 3.30; p = 0.007). MMP-7 
was predictive of poor outcome (p = 0.021) [35].
In a study by Kelner et al. in 2015, it was found that high immunohistochemical 
expression of activin A was significantly associated with presence of occult lymph 
node metastasis in oral tongue squamous cell carcinoma [36].
Non-predictors of occult lymph node metastases as shown in Table 1 include 
vascular endothelial growth factor-C (VEGF-C) and High mobility group box 1 
(HMGB1). No statistically significant difference was found between OSCC with 
and without occult lymph node metastasis in regard to VEGF-C immunoexpression 
by malignant cells [37]. Isolated VEGF-C expression by malignant cells is not of 
predictive value for occult lymph node metastasis in early stages of oral squamous 
cell carcinoma [37]. Likewise, Prediction of occurrence of late neck metastasis in 
early tongue squamous cell carcinoma by evaluating HMGB1 (high mobility group 
box 1) expression in the primary lesion showed that immunohistochemistry study 
of HMGB1 in early tongue squamous cell carcinoma did not appear to be very useful 
for predicting occult neck metastasis [38].
Most recently, immunohistochemistry quantification of partial epithelial-to-mes-
enchymal transition (p-EMT) in oral cavity squamous cell carcinoma primary tumors 
Predictor Non-predictor
Cyclin B-1






Vascular endothelial growth factor-C (VEGF-C)
High mobility group box 1 (HMGB1)
Table 1. 
Predictors and non-predictors of occult lymph node metastases in oral cavity carcinoma.
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has been reliably shown to be associated with nodal metastases, perineural invasion, 
and high grade [39]. EMT is thought to be a potential driver of invasiveness and 
metastasis in a variety of epithelial cancers [39]. It has been said that with prospective 
validation, p-EMT biomarkers may aid in decision making over whether to perform a 
neck dissection in the N0 neck and/or for adjuvant therapy planning [39].
7. Post-operative follow-up
Based on the algorithm proposed by Paler et al., follow-up CT scan may be done 
for N1 disease and PET CT for N2/N3 disease 12 weeks after treatment [40]. CT 
scan may also be done for N0 neck [1].
The NCCN guidelines follow-up recommendations for oral cavity carcinoma 
include a complete head and neck examination every 1–3 months for the first 
post-operative year, every 2–6 months for the second post-operative year, every 
4–8 months for years 3–5, and every 12 months beyond 5 years post-operatively. 
Speech/hearing and swallowing evaluation, nutritional evaluation and rehabilita-
tion, smoking cessation and alcohol counseling, and surveillance for depression are 
included in the post-operative supportive care recommendations [1].
8. Conclusions
Despite advances in imaging studies in detecting occult metastasis, the risk of 
occult metastases in necks categorized as N0 in patients with oral cavity squamous 
cell carcinoma (SCC) remains and the need for neck dissection should carefully be 
examined. Elective neck dissection, specifically, selective neck dissection, is recom-
mended for Stage II oral cavity carcinoma given the high risk of occult metastasis. 
For Stage I clinically N0 oral cavity carcinoma, elective neck dissection has been 
historically recommended for tumor thickness >4 mm but recent evidence supports 
the effectiveness of elective neck dissection in patients with oral cavity carcinoma 
>3 mm depth of invasion. The role of sentinel lymph node biopsy in detection of 
occult cervical lymph node metastasis is promising but requires technical expertise 
and experience. Identification of biomarkers in predicting the presence of cervical 
lymph node metastasis may prove to have increasing utility.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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